You have free access to this content

Alimentary Pharmacology & Therapeutics

Cover image for Vol. 36 Issue 7

October 2012

Volume 36, Issue 7

Pages 607–689

  1. SYSTEMATIC REVIEW

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Systematic review: early infant feeding and the prevention of coeliac disease (pages 607–618)

      H. Szajewska, A. Chmielewska, M. Pieścik-Lech, A. Ivarsson, S. Kolacek, S. Koletzko, M. L. Mearin, R. Shamir, R. Auricchio, R. Troncone and PREVENTCD Study Group

      Version of Record online: 21 AUG 2012 | DOI: 10.1111/apt.12023

      Corrected by:

      Corrigendum: Corrigendum

      Vol. 37, Issue 2, 287, Version of Record online: 17 DEC 2012

  2. META-ANALYSIS

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  3. RABEPRAZOLE DOSING

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype (pages 627–634)

      M. Sugimoto, N. Shirai, M. Nishino, C. Kodaira, T. Uotani, M. Yamade, S. Sahara, H. Ichikawa, K. Sugimoto, H. Miyajima and T. Furuta

      Version of Record online: 10 AUG 2012 | DOI: 10.1111/apt.12014

  4. PARTIAL RESPONSE IN GERD

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  5. GASTRIC CARCINOIDS

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Gastric carcinoids after long-term use of a proton pump inhibitor (pages 644–649)

      C. S. Jianu, R. Fossmark, T. Viset, G. Qvigstad, Ø. Sørdal, R. Mårvik and H. L. Waldum

      Version of Record online: 5 AUG 2012 | DOI: 10.1111/apt.12012

  6. REACTIONS TO INFLIXIMAB

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  7. LACTOSE INTOLERANCE

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Is the subjective perception of lactose intolerance influenced by the psychological profile? (pages 660–669)

      C. Tomba, A. Baldassarri, M. Coletta, B. M. Cesana and G. Basilisco

      Version of Record online: 1 AUG 2012 | DOI: 10.1111/apt.12006

  8. HEPATITIS C

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  9. INVITED COMMENTARIES

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Commentary: predicting survival in hepatocellular carcinoma patients (page 680)

      G. L.-H. Wong and V. W.-S. Wong

      Version of Record online: 11 SEP 2012 | DOI: 10.1111/apt.12017

    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
      Commentary: time to update the ALT cut-off? (pages 682–683)

      Z. Yu, G. L.-H. Wong and V. W.-S. Wong

      Version of Record online: 11 SEP 2012 | DOI: 10.1111/apt.12022

  10. LETTERS TO THE EDITORS

    1. Top of page
    2. SYSTEMATIC REVIEW
    3. META-ANALYSIS
    4. RABEPRAZOLE DOSING
    5. PARTIAL RESPONSE IN GERD
    6. GASTRIC CARCINOIDS
    7. REACTIONS TO INFLIXIMAB
    8. LACTOSE INTOLERANCE
    9. HEPATITIS C
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
    5. You have free access to this content
    6. You have free access to this content
    7. You have free access to this content
    8. You have free access to this content

SEARCH

SEARCH BY CITATION